- Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
- CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
- CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
- CEL-SCI Appoints Mario Gobbo to Its Board of Directors
- CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
More ▼
Key statistics
As of last trade, CEL-SCI Corp (CVM:ASQ) traded at 1.28, 22.68% above the 52 week low of 1.04 set on Oct 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.32 |
---|---|
High | 1.37 |
Low | 1.27 |
Bid | 1.27 |
Offer | 1.28 |
Previous close | 1.30 |
Average volume | 242.61k |
---|---|
Shares outstanding | 54.16m |
Free float | 52.38m |
P/E (TTM) | -- |
Market cap | 69.32m USD |
EPS (TTM) | -0.6304 USD |
Data delayed at least 15 minutes, as of Jun 10 2024 19:51 BST.
More ▼